Gastrointestinal Cancer
Dr. Fatema Tashrifwala explains new research highlighting the effectiveness of TACE plus camrelizumab.
Patients without microscopic vascular invasion had a better prognosis, and tumor number was found to be associated with pCR.
Investigators determined that progression-free survival for patients who received TACE plus camrelizumab was 6.2 months.
Investigators also researched the possibility that AI could predict progression-free survival.
Researchers performed a 2-sample Mendelian randomization analysis conducted at the genus level.
Pembrolizumab is now approved with fluoropyrimidine- and platinum-containing chemo for patients with gastric or GEJ cancer.
The study evaluated clinical outcomes associated with lenvatinib after immunotherapy treatment.
Dr. Fakih details his study and the results of the effectiveness of sotorasib plus panitumumab for KRAS G12C-mutated CRC.
A phase 3 trial sought to determine the impact of HIPEC on overall survival in patients after undergoing CRS.
Fruquintinib is the first targeted agent in more than a decade for mCRC regardless of biomarker status or prior therapy.
Advertisement
Expert Interviews on Oncology
Advertisement
DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
